// App-Quantinova.ai

M4075 2015 AHA : The Electrocardiographic Effects of Intranasal Formulations of a New Calcium Channel Blocker, MSP-2017, are Consistent with a Potential Treatment of Paroxysmal Supraventricular Tachycardia: Results of a Phase I Dose Escalation Study

Researchers

Presenter

  • Archer Broughton

Principal Investigators

  • Philippe Douville

  • Philip T Sager

  • Bob Soh

  • Douglas Wight

Medical Centers

  • The Alfred Hospital, Melbourne, Australia

  • Milestone Pharmaceuticals,Montreal St Laurent, QC, Canada

  • Nucleus Network, Melbourne, Australia

  • Milestone Pharmaceuticals,Montreal St Laurent, QC, Canada

Locations

  • United States

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Arrhythmia

Biomarkers

  • N/A

Drug/Treatment

  • Etripamil

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved